Chronic Nonbacterial Osteomyelitis

0
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Alder Therapeutics
Alder TherapeuticsSweden - Solna
1 program
MethotrexateN/A1 trial
Active Trials
NCT04725422Recruiting2,000Est. Aug 2050

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Alder TherapeuticsMethotrexate

Clinical Trials (1)

Total enrollment: 2,000 patients across 1 trials

CHronic Nonbacterial Osteomyelitis International Registry

Start: Aug 2018Est. completion: Aug 20502,000 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 2,000 patients
1 companies competing in this space